Table 5. OS and DFS in relation to SNP distributions in patients treated with anthracycline-based chemotherapy (Cox regression).
| Genotype | OS | DFS | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Cases | Events | HR | 95% CI | P | Events | HR | 95%CI | P | |
| rs17878362 | |||||||||
| A 1 A 1 | 159 | 22 | REF | - | - | 35 | REF | - | - |
| A 1 A 2 | 53 | 1 | 0.14 | 0.02–1.00 | 0.05 | 5 | 0.42 | 0.16–1.06 | 0.07 |
| A 2 A 2 | 7 | 2 | 1.86 | 0.44–7.93 | 0.40 | 3 | 2.03 | 0.62–6.61 | 0.24 |
| A 1 A 2 + A 2 A 2 | 60 | 3 | 0.35 | 0.11–1.18 | 0.09 | 8 | 0.60 | 0.28–1.28 | 0.19 |
| rs1042522 | |||||||||
| GG | 120 | 21 | REF | - | - | 33 | REF | - | - |
| GC | 82 | 4 | 0.31 | 0.11–0.90 | 0.03 | 7 | 0.34 | 0.15–0.77 | 0.01* |
| CC | 20 | 1 | 0.29 | 0.04–2.15 | 0.23 | 4 | 0.73 | 0.26–2.07 | 0.56 |
| GC+CC | 102 | 5 | 0.30 | 0.11–0.80 | 0.02* | 11 | 0.42 | 0.21–0.84 | 0.01* |
| rs12947788 | |||||||||
| CC | 189 | 21 | REF | - | - | 34 | REF | - | - |
| CT | 33 | 5 | 1.44 | 0.54–3.82 | 0.47 | 10 | 2.00 | 0.98–4.00 | 0.06 |
| TT | 2 | 0 | - | - | - | 0 | - | - | - |
| CT+TT | 35 | 5 | 1.33 | 0.50–3.53 | 0.57 | 10 | 1.80 | 0.89–3.65 | 0.10 |
The SNP rs17884306 was monomorphic in cases, thus not presented.
HR, hazard ratio; 95% CI, confidence interval. Significant results in bold; significant differences after Dunn–Bonferroni correction (P<0.02) are marked with an asterisk.